SCHEMBL21801452

SCHEMBL21801452

CCc1c(-c2nnc(S)o2)[nH]c2ccc(Cl)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT1 Q96EB6 3/20 0.44
▸ TLR8 Q9NR97 3/20 0.40
▸ TLR7 Q9NYK1 3/20 0.40
▸ TSPO P30536 1/20 0.40
▸ CNR1 P21554 7/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ HTR6 P50406 1/20 0.38
▸ TLR9 Q9NR96 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21801456 0.85 CYP1A2 (0.46) TLR8TLR7TLR9ALDH1A1CYP1A2
SCHEMBL21801503 0.83 LMNA (0.40) SIRT1KDM4EALDH1A1CYP1A2HPGD
SCHEMBL21801464 0.78 BCL2 (0.47) SIRT1CNR1KDM4ESMN1; SMN2
SCHEMBL21801466 0.77 MAPT (0.51) KDM4ECYP1A2HPGDCYP2C19SMN1; SMN2
SCHEMBL21801558 0.77 CNR1 (0.43) SIRT1CNR1
SCHEMBL21801526 0.77 CDC7 (0.48) SIRT1CNR1
SCHEMBL21801488 0.76 CNR1 (0.46) CNR1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL21801494 0.76 MAPT (0.48) CNR1CYP1A2CYP3A4HPGDCYP2C19
SCHEMBL21801557 0.75 CNR1 (0.52) CNR1
SCHEMBL21801554 0.74 MAPT (0.52) CNR1ALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220257569-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-08-18 — — US disclosed
US-20220257569-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-08-18 — — US disclosed
WO-2020051707-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220257569-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE CNR2, GPR119, CNR1 SIRT1 396/4885TLR8 2492/4885TLR7 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback